Tarsus Pharmaceuticals, Inc.
TARS
$79.44
-$0.53-0.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 366.10M | 295.52M | 233.67M | 182.95M | 129.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 366.10M | 295.52M | 233.67M | 182.95M | 129.62M |
| Cost of Revenue | 87.84M | 78.62M | 72.11M | 66.21M | 58.93M |
| Gross Profit | 278.26M | 216.90M | 161.56M | 116.74M | 70.69M |
| SG&A Expenses | 365.67M | 314.95M | 270.73M | 237.31M | 211.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 453.51M | 393.57M | 342.84M | 303.52M | 270.22M |
| Operating Income | -87.41M | -98.05M | -109.17M | -120.57M | -140.60M |
| Income Before Tax | -81.16M | -91.99M | -104.94M | -115.55M | -134.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -81.16 | -91.99 | -104.94 | -115.55 | -134.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.16M | -91.99M | -104.94M | -115.55M | -134.34M |
| EBIT | -87.41M | -98.05M | -109.17M | -120.57M | -140.60M |
| EBITDA | -85.61M | -96.42M | -107.75M | -119.34M | -139.46M |
| EPS Basic | -2.01 | -2.33 | -2.73 | -3.10 | -3.81 |
| Normalized Basic EPS | -1.23 | -1.43 | -1.65 | -1.87 | -2.31 |
| EPS Diluted | -2.01 | -2.33 | -2.73 | -3.10 | -3.81 |
| Normalized Diluted EPS | -1.23 | -1.43 | -1.65 | -1.87 | -2.31 |
| Average Basic Shares Outstanding | 162.87M | 158.65M | 154.11M | 150.07M | 143.45M |
| Average Diluted Shares Outstanding | 162.87M | 158.65M | 154.11M | 150.07M | 143.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |